Discloses a use of an anti-CD19 maytansinoid immunoconjugate in the manufacture of a medicament for the treatment of leukemia or lymphoma wherein said medicament is formulated so as to achieve an initial dose of about 55 mg/m² and a plurality of subsequent doses of about 55 mg/m², wherein the subsequent doses are separated in time from each other by about one week.